Company profile
Tempest Therapeutics, Inc.
NASDAQ:TPSTBiotechnology: Pharmaceutical Preparations
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06680258 | phase3 | not_yet_recruiting | 2025-12-01 | 2028-12-01 | Tempest Therapeutics | A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy |
| NCT04344795 | phase1 | completed | 2020-05-06 | 2024-09-25 | Tempest Therapeutics | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors |
| NCT03829436 | phase1 | completed | 2019-03-20 | 2022-09-07 | Tempest Therapeutics | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers |
FDA applications (0)
No records yet.